Modality
ERT
MOA
CAR-T BCMA
Target
CD38
Pathway
mTOR
DMD
Development Pipeline
Preclinical
~Mar 2014
→ ~Jun 2015
Phase 1
~Sep 2015
→ ~Dec 2016
Phase 2
~Mar 2017
→ ~Jun 2018
Phase 3
~Sep 2018
→ ~Dec 2019
NDA/BLA
Mar 2020
→ Sep 2030
NDA/BLACurrent
NCT05066021
555 pts·DMD
2020-03→2030-09·Not yet recruiting
555 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-09-254.5y awayPh3 Readout· DMD
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
NDA/BLA
Not yet…
Catalysts
Ph3 Readout
2030-09-25 · 4.5y away
DMD
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05066021 | NDA/BLA | DMD | Not yet recr... | 555 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 |